Ezetimibe was no better than placebo at reducing liver fat or improving liver histology in nonalcoholic steatohepatitis (NASH), results of the MOZART (Magnetic Resonance Imaging and Elastography in Ezetimibe Versus Placebo for the Assessment of Response to Treatment in NASH) trial showed.

“This trial … provides compelling evidence that ezetimibe has no specific role in the treatment of NASH,” Rohit Loomba, MD, division of gastroenterology and epidemiology, University of California at San Diego School of Medicine, La Jolla, Calif., and colleagues reported in Hepatology.